Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

Kenya is among nine African countries, under the low- and middle-income category, that are set to be among the early beneficiaries of lenacapavir, a long-acting HIV prevention drug, following a recent ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government says it has saved the lives of over 25 million people around the world ...

South Florida HIV preventative care is in jeopardy after millions of dollars in federal health care funding were cuts.

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...